登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Clinical Study of Induced Pluripotent Stem Cells Derived Motor Neuron Precursor Cell Therapy for Amyotrophic Lateral Sclerosis (ALS)
ClinicalTrials.gov 上登记的一项肌萎缩侧索硬化症开放试验,由同济大学附属东方医院牵头,本站收录的另外 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月13日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 2
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06765564,读取于 2026年11月13日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 5
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(5 项)收起清单
18 岁 至 60 岁;性别:不限
登记记录的入选字段
Poorly controlled hypertension, with systolic blood pressure >160 mmHg and/or diastolic blood pressure >100 mmHg after treatment.
排除标准第 18 条
Patients with elevated liver function test results during the screening period, such as total bilirubin >1.5 times the upper limit of normal (ULN), or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 times ULN.
排除标准第 12 条
Patients who have abnormal kidney function test results during the screening period, such as serum creatinine >1.5 mg/dL or an estimated creatinine clearance rate <60 mL/min calculated by the Cockcroft and Gault formula.
排除标准第 13 条
Coagulation abnormalities (prothrombin time [PT] or international normalized ratio [INR] >1.5 times ULN; activated partial thromboplastin time [APTT] >1.5 times ULN) or those currently receiving anticoagulation therapy.
排除标准第 17 条
Patients with hepatitis A, active hepatitis B (HBsAg positive and HBV DNA ≥500 IU/ml, excluding drug- or other-caused hepatitis), active hepatitis C (anti-HCV antibody positive and HCV RNA positive), hepatitis E, human immunodeficiency virus (HIV) antibody positive, or syphilis treponemal antibody positive.
排除标准第 15 条
Pregnant or breastfeeding women.
排除标准第 21 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);日常活动能力;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06765564,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Patients themselves or their legal guardians must consent to undergo this treatment protocol and sign the Informed Consent Form (ICF). Age between 18 and 60 years, inclusive, with no gender restrictions. Diagnosed with ALS according to the World Federation of Neurology criteria, and the initial diagnosis date is between 6 to 24 months before the screening date. Patients who have received standard treatment in the past with poor efficacy or disease progression. Forced Vital Capacity (FVC) should be ≥50%. During any night of the screening period, the total time with peripheral blood oxygen saturation <90% should not exceed 2%. Patients should be deemed by the investigator to be in good nutritional status, with a Body Mass Index (BMI) ≥18.5. Male patients and their spouses, as well as women of childbearing age, should agree to implement effective contraceptive measures from the time of signing the ICF until one year after the start of treatment. Patients should be able to cooperate in the collection and preservation of medical history data and the visit process.排除标准:Exclusion Criteria:
Patients with symptoms of neuromuscular weakness but cannot be conclusively determined to have ALS. Patients diagnosed with severe cognitive impairment, clinical dementia, or major psychiatric disorders, including but not limited to schizophrenia, bipolar disorder, or severe depression, according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V). Patients with any disease that impairs nerve or muscle function, such as peripheral neuropathy or metabolic myopathy. Patients with a history of malignant tumors or a previous diagnosis of malignancy. Within the two weeks preceding the screening period, patients who experienced acute active infections requiring treatment with antibiotics, antiviral drugs, or antifungal medications. ALS patients with concomitant respiratory failure. Patients who have previously undergone any allogeneic cell therapy or organ transplantation. Patients who have Participated in other clinical trials within the three months prior to screening. Patients with a history of tracheostomy or those using mechanical ventilatory support. Patients with a documented history of severe allergic reactions to general anesthesia drugs or previous severe allergic reactions for other reasons. Patients with intracranial organic diseases causing increased intracranial pressure. Patients with elevated liver function test results during the screening period, such as total bilirubin >1.5 times the upper limit of normal (ULN), or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 times ULN. Patients who have abnormal kidney function test results during the screening period, such as serum creatinine >1.5 mg/dL or an estimated creatinine clearance rate <60 mL/min calculated by the Cockcroft and Gault formula. Other clinically significant laboratory abnormalities during the screening period. Patients with hepatitis A, active hepatitis B (HBsAg positive and HBV DNA ≥500 IU/ml, excluding drug- or other-caused hepatitis), active hepatitis C (anti-HCV antibody positive and HCV RNA positive), hepatitis E, human immunodeficiency virus (HIV) antibody positive, or syphilis treponemal antibody positive. Patients with impaired consciousness. Coagulation abnormalities (prothrombin time [PT] or international normalized ratio [INR] >1.5 times ULN; activated partial thromboplastin time [APTT] >1.5 times ULN) or those currently receiving anticoagulation therapy. Poorly controlled hypertension, with systolic blood pressure >160 mmHg and/or diastolic blood pressure >100 mmHg after treatment. Severe diabetes with late complications; patients with other diseases affecting limb mobility (e.g., limping, osteoarthritis, rheumatoid arthritis, gout, etc.). Patients who have undergone surgery or experienced trauma (including fractures) in the past month. Pregnant or breastfeeding women. Patients who, in the opinion of the investigator, have poorly controlled systemic diseases or other conditions that make them unsuitable for participation in this clinical study.
引自 ClinicalTrials.gov, NCT06765564, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06765564,读取于 2026年11月13日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。